This inventor holds 1 USPTO granted patent. Top assignee: Fermic S.a. De C.v.. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: Gema Lopez: Innovator in Pharmaceutical Chemistry
Introduction
Gema Lopez is a notable inventor based in Mexico City, MX. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of simvastatin, a widely used cholesterol-lowering medication. His innovative methods have enhanced the efficiency and purity of simvastatin production.
Latest Patents
Gema Lopez holds a patent for a method titled "Method for alkylating the alpha carbon of the 2-methylbutyrate secondary chain of lovastatin." This patent describes a process that produces simvastatin from lovastatin in high yield and pharmaceutical purity. The method involves forming an amide of lovastatin and protecting the free hydroxyl groups using hexamethyldisilazane (HMDS). This innovative approach allows for the methylation of the alpha-carbon of the protected lovastatin amide, leading to the formation of simvastatin with minimal acidity in the reaction medium.
Career Highlights
Gema Lopez is associated with Fermic S.A. de C.V., where he has applied his expertise in pharmaceutical chemistry. His work has been instrumental in advancing methods for producing high-purity pharmaceutical compounds. His innovative techniques have the potential to streamline production processes in the pharmaceutical industry.
Collaborations
Gema has collaborated with notable colleagues, including Edvige Galeazzi and Gustavo A. Garcia. These collaborations have contributed to the development of effective pharmaceutical solutions and have fostered a productive research environment.
Conclusion
Gema Lopez is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the production of simvastatin. His innovative methods and collaborations continue to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile